Detalhe da pesquisa
1.
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 612-624, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390339
2.
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
Int J Cancer
; 151(8): 1335-1344, 2022 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603906
3.
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
Oncologist
; 27(12): 1041-1047, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35979929
4.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 380(12): 1116-1127, 2019 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30779529
5.
Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy.
BJU Int
; 129(1): 80-92, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34107167
6.
Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.
Support Care Cancer
; 30(8): 6583-6591, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35484315
7.
Immune checkpoint inhibitors-induced nephropathy: a French national survey.
Cancer Immunol Immunother
; 70(11): 3357-3364, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34155532
8.
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 21(12): 1563-1573, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33284113
9.
Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors.
Invest New Drugs
; 38(1): 160-171, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31402427
10.
The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.
Br J Cancer
; 118(9): 1179-1188, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29563634
11.
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.
Br J Cancer
; 117(7): 947-953, 2017 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28850564
12.
Cabozantinib: a new first-line option for papillary renal cell carcinoma?
Lancet
; 397(10275): 645-647, 2021 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33592177
13.
Correction to: Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors.
Invest New Drugs
; 39(1): 287-292, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32500464
14.
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Eur J Cancer
; 201: 113589, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38382153
15.
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.
J Exp Clin Cancer Res
; 43(1): 86, 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38504270
16.
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
Eur Urol
; 85(3): 274-282, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37271630
17.
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
Eur J Cancer
; 204: 114048, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653033
18.
A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma.
Mol Oncol
; 17(7): 1379-1401, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36810959
19.
Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer.
Pharmaceutics
; 15(2)2023 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36839973
20.
Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.
Clin Genitourin Cancer
; 21(6): 643-652, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37635052